Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rodatristat Ethyl in Pulmonary Arterial Hypertension
NCT04712669Phase 2Completed
- Sponsor
- Altavant Sciences
- Start
- Mar 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of rodatristat in pulmonary arterial hypertension (PAH) (8 arms), sponsored by Altavant Sciences. Primary endpoint: Pulmonary Vascular Resistance at 24 weeks. Started Mar 2021; status: completed.
02
Drugs
rodatristat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04712669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04712669.